MT2A knockdown enhances oxaliplatin sensitivity in HT29 OR cells MT2A interacts with BARD1/BRCA1 and positively regulates and promotes oxaliplatin resistance in colorectal cancer cells (15). This evidence concerns the gene MT2A and colorectal cancer.